Millions lack access to palliative care, says Human Rights Watch
Tens of millions of people worldwide are
denied access to inexpensive medications for severe pain, Human Rights Watch
said in a report released earlier this month. The 128-page report, "Global State
of Pain Treatment: Access to Palliative Care as a Human Right,"
details the failure of many governments to take even basic steps to ensure that
people with severe pain due to cancer, HIV, and other serious illnesses have
access to palliative care. As a result, millions of patients live and die in
great agony that could easily be prevented, Human Rights Watch said.
Experts estimate that 60 percent of
those who die each year in low- and middle-income countries - 33 million people
- need palliative care. In these countries, most cancer patients are diagnosed
when they already have advanced disease and can no longer be cured. The only
treatment option is palliative care. In high-income countries, palliative care
needs are increasing with aging populations and the resulting higher cancer
The report is based on a survey of
policy barriers to palliative care in 40 countries and an assessment of the
availability of pain-relieving drugs worldwide.
Human Rights Watch found that in 35 of
192 countries reviewed, fewer than 1% of patients with moderate to severe pain
from terminal cancer or HIV could get the strong pain medications they needed.
These countries are concentrated in Sub-Saharan Africa, but some are in Asia,
the Middle East, North Africa, and Central America.
Availability of strong pain medications
is very limited in many of the world's most populous countries, Human Rights
Watch found. At least 100,000 people die from cancer or HIV/AIDS each year
without access to adequate pain treatment in countries such as China, India,
Indonesia, Nigeria, Russia, and South Africa. ~ Human Rights Watch, June 2
Get the Free Mercator Newsletter
Get the news you may not get anywhere else, delivered right to your inbox.
Your info is safe with us, we will never share or sell you personal data.
Have your say!
Join Mercator and post your comments.